|drug2402||Percutaneous Coronary Revascularization for STEMI Wiki||0.71|
|D009203||Myocardial Ischemia NIH||0.20|
There are 2 clinical trials
The ISACS STEMI COVID-19 has been established in response to the emerging outbreak of COVID-19 to provide a European overview to estimate the real impact of COVID-19 pandemic on treatment and outcome of STEMI by primary angioplasty, and to identify any potential category of patients at risk for delay to treatment or no presentation.
Description: Number of patients undergoing primary angioplastyMeasure: Number of patients undergoing primary angioplasty Time: March April 2019 and 2020
Description: Number of patients undergoing primary angioplasty later 12 hours from symptoms onset;Measure: Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset; Time: March April 2019 and 2020
Description: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admissionMeasure: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission Time: March April 2019 and 2020
Description: In-Hospital mortalityMeasure: In-hospital mortality Time: March April 2019 and 2020
The epidemic of covid-19 has spread all over the world and has a great impact on people's health and life. It is necessary to study the treatment of STEMI patients in the real world under the influence of the epidemic,which provide effective suggestions and strategies for emergency and severe treatment.
Description: cardiovascular death, re-infarction, malignant arrhythmia,heart failure, revascularization, and strokeMeasure: MACE (major adverse cardiovascular events) Time: 1 year
Description: death caused by all reasonMeasure: all-cause death Time: 1 year
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports